Patent intelligence · US
US 11213524
Pharmaceutical compositions for subcutaneous administration of levosimendan
Pharmaceutical compositions for subcutaneous administration of levosimendan
Patent details — US 11213524
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 4, 2022
- Expiration
- Dec 30, 2041
- Applicant
- TENAX THERAPEUTICS, INC.
- Claims
- 19
- CPC classes
- A61K, A61K31/50, A61K47/40, A61K9/0019
Quick answer
US 11213524 (Pharmaceutical compositions for subcutaneous administration of levosimendan) is held by TENAX THERAPEUTICS, INC.. Status: granted. Granted Jan 4, 2022. Expires Dec 30, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TENAX THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/50, A61K47/40, A61K9/0019, A61K9/19
More from TENAX THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 11969424
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11701355
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted -
US 11607412
Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
granted
Frequently asked questions
What is US patent 11213524?
US 11213524 (Pharmaceutical compositions for subcutaneous administration of levosimendan) is held by TENAX THERAPEUTICS, INC.. Status: granted. Granted Jan 4, 2022. Expires Dec 30, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11213524?
TENAX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11213524 expire?
Our index shows an expiration date of Dec 30, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.